Impact of different stent alloys on human vascular response to everolimus-eluting stent: An optical coherence tomography study: The OCTEVEREST

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 3, 2013, Pages 510-518

  Guagliumi, Giulio ^a   Capodanno, Davide ^b   Ikejima, Hideyuki ^a   Bezerra, Hiram G ^c   Sirbu, Vasile ^a   Musumeci, Giuseppe ^a   Fiocca, Luigi ^a   Lortkipanidze, Nikoloz ^a   Vassileva, Angelina ^a   Tahara, Satoko ^c   Valsecchi, Orazio ^a   Costa, Marco A ^c  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

drug eluting stent; optical coherence tomography; percutaneous coronary intervention

Indexed keywords

CHROMIUM DERIVATIVE; COBALT CHROMIUM COMPLEX; COBALT COMPLEX; EVEROLIMUS; PLATINUM CHROMIUM COMPLEX; PLATINUM COMPLEX; POLY(VINYLIDENE FLUORIDE HEXAFLUOROPROPYLENE); POLYBUTYLMETHACRYLATE; POLYMER; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BIFURCATION LESION; CORONARY STENT; DRUG ELUTING STENT; EMBEDDING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMPLANTATION; IN VIVO STUDY; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MALE; OPTICAL COHERENCE TOMOGRAPHY; PREVALENCE; QUANTITATIVE CORONARY ANGIOGRAPHY; SEX DIFFERENCE; STENT ECCENTRICITY INDEX; STENT EXPANSION; STRUT MALAPPOSITION; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROSPECTIVE STUDIES; SIROLIMUS; TOMOGRAPHY, OPTICAL COHERENCE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84874115341     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24374     Document Type: Article

References (26)

1. Garg S, Serruys PW,. Coronary stents: Looking forward. J Am Coll Cardiol 2010; 56: S43-S78.
2. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
3. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
4. Allocco DJ, Jacoski MV, Huibregtse B, Mickley T, Dawkins KD,. Platinum chromium stent series-The TAXUSTM ElementTM (IONTM), PROMUS ElementTM and OMEGATM Stents. J Interv Cardiol 2011; 6: 134-141.
5. Stone GW, Terstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesiosns) trial. J Am Coll Cardiol 2011; 57: 1700-1708.
6. Meredith IT, Whitbourn R, Scott D, et al. PLATINUM QCA: A prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chormium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention 2011; 7: 84-90.
7. Claessen BE, Caixeta A, Henriques JP, Piek JJ,. Current status of the Xience V® everolimus-eluting coronary stent system. Exp Rev Cardiovasc Ther 2010; 8: 1363-1374.
8. van der Zwet PM, Reiber JH,. A new approach for the quantification of complex lesion morphology: The gradient field transform; basic principles and validation results. J Am Coll Cardiol 1994; 24: 216-224.
9. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: Three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006; 47: 2172-2179.
10. Guagliumi G, Sirbu V,. Optical coherence tomography: High resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008; 72: 237-247.
11. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI,. Intracoronary optical coherence tomography: A comprehensive review clinical and research applications. JACC Cardiovasc Interv 2009; 2: 1035-1046.
12. Guagliumi G, Costa MA, Sirbu V, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: Optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 2011; 123: 274-281.
13. Guagliumi G, Musumeci G, Sirbu V, et al. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2010; 3: 531-539.
14. Barlis P, Dimopoulos K, Tanigawa J, et al. Quantitative analysis of intracoronary optical coherence tomography measurements of stent strut apposition and tissue coverage. Int J Cardiol 2010; 141: 151-156.
15. Gutiérrez-Chico JL, Serruys PW, Girasis C, et al. Quantitative multi-modality imaging analysis of a fully bioresorbable stent: A head-to-head comparison between QCA, IVUS and OCT. Int J Cardiovasc Imaging 2011 Feb 26. [Epub ahead of print].
16. Chung WS, Park CS, Seung KB, et al. The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol 2008; 125: 325-331.
17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
18. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
19. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58: 1569-1577.
20. Guagliumi G, Sirbu V, Musumeci G, et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv 2010; 3: 367-375.
21. Guagliumi G, Ikejima H, Sirbu V, et al. Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses. The LongOCT Study (Optical Coherence Tomography in Long Lesions). JACC Cardiovasc Interv 2011; 4: 778-785.
22. Brott BC,. Linking drug-eluting stent kinetics and clinical outcomes: Insights from optical coherence tomography. JACC Cardiovasc Interv 2011; 4: 786-788.
23. O'Brien BJ, Stinson JS, Larsen SR, Eppihimer MJ, Carroll WM,. A platinum-chromium steel for cardiovascular stents. Biomaterials 2010; 31: 3755-3761.
24. Eshtehardi P, Cook S, Wandel S, et al. Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study. EuroIntervention 2010; 6: 467-474.
25. Canan T, Lee MS,. Drug-eluting stent fracture: Incidence, contributing factors and clinical implications Cath Cardiov Interv 2010; 75: 237-245.
26. Ozaki Y, Okumura M, Ismail TF, et al. The fate of incomplete stent apposition with drug-eluting stents: An optical coherence tomography-based natural history study. Eur Heart J. 2010; 31: 1470-1476.